At the time of writing, Syndax Pharmaceuticals Inc [SNDX] stock is trading at $15.68, up 4.32%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have gain 6.09% over the last week, with a monthly amount drifted -3.57%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On August 05, 2025, BTIG Research reiterated its Buy rating and revised its price target to $56 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $18 on July 10, 2025. UBS initiated its recommendation with a Buy and recommended $37 as its price target on October 24, 2024. Jefferies started tracking with a Buy rating for this stock on June 28, 2024, and assigned it a price target of $37. In a note dated January 31, 2024, Scotiabank downgraded an Sector Perform rating on this stock and revised its target price from $36 to $23.
For the past year, the stock price of Syndax Pharmaceuticals Inc fluctuated between $8.58 and $22.50. Currently, Wall Street analysts expect the stock to reach $32.33 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $15.68 at the most recent close of the market. An investor can expect a potential return of 106.19% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
According to Syndax Pharmaceuticals Inc [NASDAQ:SNDX], the company’s sales were 78.18M for trailing twelve months, which represents an 984.51% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -4.34%, Pretax Profit Margin comes in at -4.28%, and Net Profit Margin reading is -4.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -1.3 and Total Capital is -0.7. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.08 points at the first support level, and at 14.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.06, and for the 2nd resistance point, it is at 16.44.
Ratios To Look Out For
It is important to note that Syndax Pharmaceuticals Inc [NASDAQ:SNDX] has a current ratio of 4.71. As well, the Quick Ratio is 4.55, while the Cash Ratio is 0.96. Considering the valuation of this stock, the price to sales ratio is 17.28, the price to book ratio is 8.57.
Transactions by insiders
Recent insider trading involved Metzger Michael A, Chief Executive Officer, that happened on Sep 08 ’25 when 0.16 million shares were sold. Director, MICHAEL METZGER completed a deal on Sep 08 ’25 to buy 0.16 million shares. Meanwhile, Director Podlesak Dennis sold 19200.0 shares on Aug 18 ’25.
